GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » Median PS Value

Cosmo Pharmaceuticals NV (XSWX:COPN) Median PS Value : CHF119.94 (As of May. 16, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Cosmo Pharmaceuticals NV's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was CHF6.301. Cosmo Pharmaceuticals NV's 10-Year median PS Ratio is 19.0351. Therefore, the Median PS Value for today is CHF119.94.

As of today (2024-05-16), Cosmo Pharmaceuticals NV's share price is CHF73.60. Cosmo Pharmaceuticals NV's Median PS Value is CHF119.94. Therefore, Cosmo Pharmaceuticals NV's Price to Median PS Value for today is 0.61.

The historical rank and industry rank for Cosmo Pharmaceuticals NV's Median PS Value or its related term are showing as below:

XSWX:COPN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.51   Med: 0.96   Max: 3.75
Current: 0.61

During the past 13 years, the highest Price to Median PS Value of Cosmo Pharmaceuticals NV was 3.75. The lowest was 0.51. And the median was 0.96.

XSWX:COPN's Price-to-Median-PS-Value is ranked better than
76.09% of 506 companies
in the Drug Manufacturers industry
Industry Median: 0.86 vs XSWX:COPN: 0.61

Cosmo Pharmaceuticals NV Median PS Value Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Median PS Value Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.94 89.15 88.13 78.33 119.94

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 78.33 - 119.94 -

Competitive Comparison of Cosmo Pharmaceuticals NV's Median PS Value

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmo Pharmaceuticals NV's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's Price-to-Median-PS-Value falls into.



Cosmo Pharmaceuticals NV Median PS Value Calculation

Cosmo Pharmaceuticals NV's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=6.301*19.0351
=119.94

10-Year Median PS Ratio is 19.0351.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Pharmaceuticals NV's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was CHF6.301.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosmo Pharmaceuticals NV  (XSWX:COPN) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Cosmo Pharmaceuticals NV's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=73.60/119.94
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosmo Pharmaceuticals NV Median PS Value Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (XSWX:COPN) Headlines

No Headlines